Enlivex Granted FDA Fast-Track Designation for Knee Osteoarthritis Therapy

The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Enlivex Therapeutics' experimental drug, Allocetra, for the treatment of age-related knee osteoarthritis. The designation, which applies to patients aged 64 and older, signals a potentially expedited path to market for the novel immunotherapy.

Pathway to Accelerated Review

The RMAT designation is intended for regenerative medicine therapies that have shown preliminary clinical evidence of addressing an unmet medical need for a serious condition. This status provides significant benefits to Enlivex, including:

• More frequent and early-stage interactions with the FDA.
• Eligibility for accelerated approval and priority review, which can shorten the standard drug approval timeline.

The designation was granted based on promising data from a completed Phase I/IIa trial. In that study, patients treated with Allocetra demonstrated statistically significant improvements in pain and physical function compared to a placebo, with the positive effects lasting for at least six months.

Next Steps and Clinical Trials

Ad

Enlivex has initiated a randomized, controlled Phase IIb trial across the U.S. and Europe to further evaluate Allocetra. The study aims to enroll 182 patients aged 64 and older with primary knee osteoarthritis, and the first U.S. patient has already been dosed. The company anticipates releasing top-line data from this trial by the end of the second quarter of 2027.

Additionally, the FDA has requested a Type B meeting with Enlivex to discuss the broader development program for Allocetra, including the design of its Phase IIb and future pivotal trials. The company stated it plans to schedule this meeting in the coming months.

Market Context

Knee osteoarthritis is a degenerative joint disease that currently affects more than 32 million Americans, a figure projected to increase to approximately 78 million by 2040. Current treatment options are limited, particularly for the large and growing aging population, with severe cases often culminating in total knee replacement surgery. The RMAT designation positions Allocetra as a potentially significant future treatment for this widespread condition.